RET PHOTOSWITCH | THE DEVELOPMENT OF NOVEL PHOTOSWITCHABLE KINASE INHIBITORS

Summary
The overall research objective of this project is to develop novel photoswitchable kinase inhibitors (PKIs), targeting on REarrange during Transfection (RET) for use in living cells and in zebrafish (Danio rerio). Controlling the action of kinases in a reversible way will have an exceptional potential for investigating signal transduction in zebrafish. In this work, photoswitchable RET kinase inhibitors based on azo-functionalized pyrazolopyrimidines will be developed, enabling photonic control of RET activity with substantial differences in inhibitory activity between the two photoisomeric forms. Such RET inhibitors are currently not available. RET is expressed by the immune cells of the brain, the microglia and is mediating activation of the cells. Microglia has been shown to be responsible for both protecting and harmful effects in neurodegenerative disorders. Although RET has been shown to be involved in neurodegeneration, its role in Alzheimer’s disease (AD), where microglia play an important role, is not known. The ability to manipulate the activity of RET using light would result in temporal control of enzymatic activity, thus serving as a valuable molecular tool to study the function of RET in microglia cells and further our understanding of AD.

The research project is (1) highly interdisciplinary, (2) timely due to the recent interest of photopharmacology and (3) innovative by combining zebrafish imaging with photopharmacology to study signalling relevant for development of AD. This fellowship will ensure the best possible career opportunities for me as I will receive substantial training in cutting-edge approaches, gain mentor and supervision skills, presentation skills and critical assessment skills, largely expand my collaborative network, and gain the fundaments for becoming a mature, independent researcher within the field of chemical biology.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/797049
Start date: 01-10-2018
End date: 30-09-2020
Total budget - Public funding: 185 857,20 Euro - 185 857,00 Euro
Cordis data

Original description

The overall research objective of this project is to develop novel photoswitchable kinase inhibitors (PKIs), targeting on REarrange during Transfection (RET) for use in living cells and in zebrafish (Danio rerio). Controlling the action of kinases in a reversible way will have an exceptional potential for investigating signal transduction in zebrafish. In this work, photoswitchable RET kinase inhibitors based on azo-functionalized pyrazolopyrimidines will be developed, enabling photonic control of RET activity with substantial differences in inhibitory activity between the two photoisomeric forms. Such RET inhibitors are currently not available. RET is expressed by the immune cells of the brain, the microglia and is mediating activation of the cells. Microglia has been shown to be responsible for both protecting and harmful effects in neurodegenerative disorders. Although RET has been shown to be involved in neurodegeneration, its role in Alzheimer’s disease (AD), where microglia play an important role, is not known. The ability to manipulate the activity of RET using light would result in temporal control of enzymatic activity, thus serving as a valuable molecular tool to study the function of RET in microglia cells and further our understanding of AD.

The research project is (1) highly interdisciplinary, (2) timely due to the recent interest of photopharmacology and (3) innovative by combining zebrafish imaging with photopharmacology to study signalling relevant for development of AD. This fellowship will ensure the best possible career opportunities for me as I will receive substantial training in cutting-edge approaches, gain mentor and supervision skills, presentation skills and critical assessment skills, largely expand my collaborative network, and gain the fundaments for becoming a mature, independent researcher within the field of chemical biology.

Status

CLOSED

Call topic

MSCA-IF-2017

Update Date

28-04-2024
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.1. EXCELLENT SCIENCE
H2020-EU.1.3. EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions (MSCA)
H2020-EU.1.3.2. Nurturing excellence by means of cross-border and cross-sector mobility
H2020-MSCA-IF-2017
MSCA-IF-2017